Abstract | UNLABELLED: OBJECTIVE: METHOD: A case report of a 19-year-old female patient with tic disorder who had taken haloperidol 2 mg/d with benzhexol HCl 2-4 mg/d, then switched to risperidone 1.5 mg/d with benzhexol HCl 4 mg/d because of acute dystonia and oculogyric. She was then prescribed quetiapine, 50 mg/d as a starting dose without benzhexol HCI, because of the remaining symptoms and EPS. The severity of the symptoms was assessed monthly using the Behavior Rating Scale. The dose was increased by 50 mg/d weekly for a better outcome. RESULTS: The tic was improved after the first week and disappeared for three weeks with 150 mg/d of quetiapine. However, the tic returned again, but less frequently (20%). Thus, the dose was stepped up to 200 mg/d. One week later, the patient reported that the tic has disappeared. CONCLUSION:
Quetiapine showed the efficacy and fewest EPS in this patient. However, a further clinically controlled trial must be carried out before quetiapine can become the first-line treatment for tic disorders.
|
Authors | T Chan-Ob, N Kuntawongse, V Boonyanaruthee |
Journal | Journal of the Medical Association of Thailand = Chotmaihet thangphaet
(J Med Assoc Thai)
Vol. 84
Issue 11
Pg. 1624-8
(Nov 2001)
ISSN: 0125-2208 [Print] Thailand |
PMID | 11853307
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Dibenzothiazepines
- Quetiapine Fumarate
- Haloperidol
- Risperidone
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Dibenzothiazepines
(therapeutic use)
- Female
- Haloperidol
(therapeutic use)
- Humans
- Quetiapine Fumarate
- Risperidone
(therapeutic use)
- Tic Disorders
(drug therapy)
|